D****u
发帖数: 162 | 1 (Reuters) - Ariad Pharmaceuticals' (ARIA.O) shares fell 3 percent on
Wednesday morning after a U.S. Food and Drug Administration panel did not
recommend the company's experimental cancer candidate.
On Wednesday, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 13-1
that the benefits of the company's investigational agent ridaforolimus did
not outweigh its risks.
"We no longer assume approval on the June 5, 2012 PDUFA (action) date,"
Stifel Nicolaus analyst Joel Sendek said, and cut his ... 阅读全帖 |
|
m******c
发帖数: 1202 | 2 Would Pfizer buy Ariad?
Yes. Would Dr. Berger sell it? It depends on the offered price. I do not
think Dr. Berger would sell Ariad at any prices below my 1st target price $
48.50. The poison pills were placed in when ARIA was at $20+ in 2000.
I invited 6 Ariad employees to a BBQ party in 1999. At that time, Ariad had
0 cancer drugs and its financial statements looked terrible. Its market
capital was below (30m?). At the BBQ party, a scientist (he is still at
Ariad now) complaining Dr. Berger's r... 阅读全帖 |
|
f**********g
发帖数: 2252 | 3 Just saw the news, +39% now.
Ariad Pharmaceuticals Shares Up 29% After A Drug Study Showed Positive
Results (ARIA)
3 hours 7 minutes ago - PSM
Comtex SmarTrend(R)Ariad Pharmaceuticals (NASDAQ:ARIA) shares are trading 29
.33% higher at $6.79 after the company said that a study showed its drug for
sarcomas helped slow the disease's advance, according to a Bloomberg report
.
Ariad Pharmaceuticals has a potential upside of 1.9% based on a current
price of $6.54 and an average consensus analyst price... 阅读全帖 |
|
f**********g
发帖数: 2252 | 4 Just saw the news, +39% now.
Ariad Pharmaceuticals Shares Up 29% After A Drug Study Showed Positive
Results (ARIA)
3 hours 7 minutes ago - PSM
Comtex SmarTrend(R)Ariad Pharmaceuticals (NASDAQ:ARIA) shares are trading 29
.33% higher at $6.79 after the company said that a study showed its drug for
sarcomas helped slow the disease's advance, according to a Bloomberg report
.
Ariad Pharmaceuticals has a potential upside of 1.9% based on a current
price of $6.54 and an average consensus analyst price... 阅读全帖 |
|
E**********r
发帖数: 2743 | 5 ARIA下周二（1月14日）前后应该会涨。
ARIAD to Present at JPM Conference
”The global oncology company ARIAD Pharmaceuticals Inc. (ARIA) will
participate in the 32nd annual J.P. Morgan Healthcare Conference in San
Francisco, on Jan 14, 2014. The presentation will focus on the company’s
overall business.
We expect the company to provide an update on its sole marketed product,
Iclusig. ARIAD will resume selling Iclusig from mid-Jan 2014 under a
modified prescribing and risk management plan approved by the U.S. Foo... 阅读全帖 |
|
m******c
发帖数: 1202 | 6 Ever since Ariad Pharmaceuticals’ Ponatinib treatment for leukemia was
given the green light by American regulator, the FDA, industry majors have
been sniffing around. As its shares changed hands at $6.50, valuing the
Massachusetts-based company at around £800m, dealers heard whispers
from across the Pond that at least three international pharma groups
including US giant Eli Lilly have made ‘friendly approaches’ to the Ariad
board and are prepared to pay up to $20 a share in cash to gain co... 阅读全帖 |
|
f**********g
发帖数: 2252 | 7 Got it. Good news on 5/4 ER.
Ariad Pharmaceuticals (ARIA) based in Cambridge, MA, engages in the
discovery and development of small-molecule drugs for the treatment of
cancer. On Wednesday evening, the company released its 1Q 2011 earnings and
hosted a conference Thursday morning discussing the report. Much of the
report was expected; however, management announced that the pivotal phase 2
trial for ponatinib, called PACE, was on track for significantly early
enrollment (six months early!). This ... 阅读全帖 |
|
E**********r
发帖数: 2743 | 8 Ariad +9%, reports commercial availability of Iclusig for adult CML patients
Jan 17 2014, 08:25
Ariad Pharmaceuticals (ARIA) +9% premarket after announcing the commercial
availability of Iclusig for adult patients with refractory chronic myeloid
leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia
in the U.S.
ARIA has begun shipping Iclusig to Biologics, its exclusive specialty
pharmacy, which is now filling prescriptions from physicians and
distributing the cancer medicine... 阅读全帖 |
|
E**********r
发帖数: 2743 | 9 (turkey FA, YMYD)
可以关注下SYN （Biologics Inc.），貌似也会涨。
Biologics, Inc., an integrated oncology services company, is pleased to
announce that it has been selected by ARIAD Pharmaceuticals, Inc. (ARIA) to
be the sole specialty pharmacy provider of Iclusig® (ponatinib) and
manager of its Patient Access and Support Services (ARIAD PASSTM) program.
。。。
http://finance.yahoo.com/news/biologics-selected-ariad-exclusiv |
|
V*****2
发帖数: 7930 | 10 Representatives from Ariad and its reported suitors would not discuss the
market frenzy or the Mail’s report, citing longstanding company policies.
“We don’t comment on rumors and speculation,” said Ariad spokeswoman Liza
Heapes.
“It is our policy at Lilly not to comment on market rumors or deal
speculation,” said Mark Taylor, a spokesman for Eli Lilly.
Shire and GlaxoSmithKline similarly declined to talk about whether they were
interested in Ariad. |
|
|
r******e
发帖数: 361 | 12 This item was adjusted to emphasize that Ariad is looking for a partner in
Japan for Iclusig, rather than a general partnership.
Ariad on the move on Iclusig partnership chatter • 3:45 PM
Citing CEO Harvey Berger, DealReporter says Ariad (ARIA +4.4%) is looking
for a partner in Japan for Iclusig, with an announcement perhaps coming soon.
From this week's earnings call (transcript): "In addition to actively
pursuing distribution agreements for Iclusig in central and eastern Europe,
as well ... 阅读全帖 |
|
n****8
发帖数: 294 | 13 Partial Clinical Hold on Ariad (ARIA) Study Lifted: Ariad’s investors
finally had something to cheer about with the FDA lifting a partial clinical
hold on the company’s phase II study of Iclusig in patients with
refractory metastatic and/or unresectable gastrointestinal stromal tumors.
New patients can now be enrolled in this study. Ariad also presented initial
data which indicate Iclusig’s anti-tumor activity in patients with
advanced GIST, particularly in patients with KIT exon 11 mutations. S... 阅读全帖 |
|
b*****p
发帖数: 9649 | 14 by http://www.guancha.cn/xiaopengcai
星期五传出来Ariad Pharmaceuticals($ARIA)公司内部董事会开始内斗。目前这家公司
的最大股东是萨瑞莎资本公司（Sarissa Capital）拥有6.9%的股份。自从这家维权对
冲基金公司（Activist Hedge Fund）入主这家公司，市场上就开始有心理准备这场即
将到来震荡。萨瑞莎资本公司的创始人叫Alex Denner，今年45岁，是真正的高富帅啊
。这人麻省理工大学本科毕业，耶鲁大学生物医学工程专业博士，博士毕业后在华尔街
摩根斯坦利（Morgan Stanley）和维京全球投资公司（Viking Global Investors）做
医药和生物科技基金经理，后来拜入卡尔·伊卡恩（Carl Icahn）门下统管医药和生物
科技对冲基金，成为卡尔·伊卡恩门生。这人非常内行专业，很懂得分析生物医药公司
的内在价值并把这种价值体现在商业价值上。2012年羽翼丰满脱离卡尔集团自创萨瑞莎
对冲基金公司。
我在前面2月8日文章“大鱼吃小鱼，小鱼吃虾米”中有提到卡尔·伊卡恩是一个传奇投
资... 阅读全帖 |
|
|
|
w******3
发帖数: 32 | 17 请帮忙打听一下此药的购买价格：
美国ARIAD Pharmaceuticals, Inc公司生产的新型mTOR 抑制剂AP23573产品，用于治疗
软组织及骨肉瘤。
附该公司的联系信息：
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139-4234
Telephone: (617) 494-0400
Facsimile: (617) 494-8144 |
|
f**********g
发帖数: 2252 | 18 ER tomorrow or was 5/4?
On 5/4/2011, ARIA reported 1st quarter 2011 losses of $0.29 per share. This
result missed the $0.13 loss expectation of the 7 analysts following the
company and missed last year's 1st quarter results by 38.10%.
Earnings Look Ahead: In 1 Day, Ariad Pharmaceuticals Releases Its Quarterly
Numbers (ARIA)
8 hours 36 minutes ago - Comtex SmarTrend(R) via Comtex
Comtex SmarTrend(R)Analysts, on average, expect Ariad Pharmaceuticals (
NASDAQ:ARIA) to report a loss of $0.15 per sha... 阅读全帖 |
|
j****d
发帖数: 123 | 19 Seems wrong choice: Taxotere 多西他赛 没有啥用的
人在哪国?
在美国的话, 请马上联系以下新药药试
LDK378 by Novartis
AP26113 by Ariad
Xalkori 用了多久? |
|
j****d
发帖数: 123 | 20 Seems wrong choice: Taxotere 多西他赛 没有啥用的
人在哪国?
在美国的话, 请马上联系以下新药药试
LDK378 by Novartis
AP26113 by Ariad
Xalkori 用了多久? |
|
w****r
发帖数: 245 | 21 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
l********i
发帖数: 2503 | 22 ARIAD expects to file for regulatory approval of ponatinib in the EU and in
the U.S. in Q3 of 2012 based on these clinical data.
在９月３０日前尽量BUY DIP。 |
|
|
s******t
发帖数: 213 | 24 ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of
Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias |
|
|
|
|
s******t
发帖数: 213 | 28 等欧洲的消息了。应该没问题。很不明白fda做决策的过程，这个药减少剂量之后副作
用是大大的减小，而药效减小的速度远小于副作用的减少速率，可为什么fda都没有让
ariad调整剂量而只是加了个label呢。。。 |
|
E**********r
发帖数: 2743 | 29 今天开会的时候股市都关门了，明天涨吧》》》》》
（ZT）
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the 32(nd) Annual J.P. Morgan Healthcare Conference being held in
San Francisco. Harvey J. Berger, M.D., chairman and chief executive officer
, will provide an overview of the Company's business on Tuesday, January 14
at 3:00 p.m. (PT). |
|
|
|
R******o
发帖数: 1572 | 32 你牛
这种penny stock我根本不敢碰的 |
|
|
|
U******E
发帖数: 444 | 35 ARIA 的pipline应该还是不错的，CML milestone 第3代 kinase inhibitor 很快又要
重新上市 |
|
|
|
b*d
发帖数: 3069 | 38 你是怎么能够一直拿住的啊？
这种暴跌股票很多就一路向南了。尤其药股，一般是什么药fail了
你当时是怎么考虑的呢？ |
|
|
|
|
|
|
|
|
m******3
发帖数: 983 | 46 Can pop to 10 easily. Hold on |
|
|
|
|
|
